COMP <GO>
DXCM vs JNJ // PIOTROSKI F-SCORE QUALITY
DexCom Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: DXCM 5
— JNJ 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: DXCM
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
piotroski-score
9/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 67.90% | -7.80 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 25.50% | -3.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 18.5x | +6.70 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 2.97% | +0.60 | DXCM | /fcf-yield <GO> |
| Operating Margin | 19.60% | 34.70% | -15.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 28.50% | -10.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 6.00% | +9.60 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 5.59 | +1.55 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 8/9 | +1.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 60.4 | -12.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 23.0x | +7.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $662.49B | -$632.33B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | JNJ REV | DXCM GROSS % | JNJ GROSS % | DXCM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $94.19B | 60.1% | 67.9% | $1.08B | $19.70B |
| FY 2024 | $4.03B | $88.82B | 60.5% | 69.1% | $630.7M | $19.84B |
| FY 2023 | $3.62B | $85.16B | 44.0% | 44.0% | $585.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
JNJ // BETA 1.08